$ cat ./records/gates-foundation-partners-with-serum-institute-of-india-on-100-mi-2020.txt
Gates Foundation Partners with Serum Institute of India on 100 Million COVID-19 Vaccine Doses
[RECORD.TXT] · cat --full
The Gates Foundation committed $150 million — later doubled to $300 million — to an at-risk manufacturing deal with Gavi and Serum Institute of India (the world's largest vaccine manufacturer by volume) to produce 100 million COVID-19 vaccine doses for low- and middle-income countries at no more than $3 per dose. The deal de-risked early production when no vaccine had yet been approved and was credited with ensuring that COVAX had supply when doses were urgently needed in 2021.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Co-Funds $100 Million Africa Pathogen Genomics Initiative
Next →
Gates Foundation committed COVID-19 emergency response grants to BRAC and BRAC USA, supporting programs reaching Rohingya refugees in Bangladesh
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.